


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:00:56Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12408013" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12408013</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Res Sq</journal-id><journal-id journal-id-type="pmc-domain-id">3885</journal-id><journal-id journal-id-type="pmc-domain">ressq</journal-id><journal-id journal-id-type="publisher-id">ResearchSquare</journal-id><journal-title-group><journal-title>Research Square</journal-title></journal-title-group><issn pub-type="epub">2693-5015</issn><publisher><publisher-name>American Journal Experts</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12408013</article-id><article-id pub-id-type="pmcid-ver">PMC12408013.1</article-id><article-id pub-id-type="pmcaid">12408013</article-id><article-id pub-id-type="pmcaiid">12408013</article-id><article-id pub-id-type="pmid">40909807</article-id><article-id pub-id-type="doi">10.21203/rs.3.rs-7411649/v1</article-id><article-id pub-id-type="other">10.21203/rs.3.rs-7411649</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>
Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma
</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gonzalez-Aponte</surname><given-names initials="MF">Maria F.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yitong</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leidig</surname><given-names initials="WA">William A.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simon</surname><given-names initials="T">Tatiana</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butt</surname><given-names initials="OH">Omar H.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruben</surname><given-names initials="MD">Marc D.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="AH">Albert H.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rubin</surname><given-names initials="JB">Joshua B.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herzog</surname><given-names initials="ED">Erik D.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walch</surname><given-names initials="OJ">Olivia J.</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>29</day><month>8</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">496187</issue-id><elocation-id>rs.3.rs-7411649</elocation-id><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-05 10:25:38.007"><day>05</day><month>09</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="nihpp-rs7411649v1.pdf"/><self-uri xlink:href="https://www.researchsquare.com/article/rs-7411649/v1">https://www.researchsquare.com/article/rs-7411649/v1</self-uri><self-uri content-type="pdf">nihpp-rs7411649v1.pdf</self-uri><abstract><title>Abstract</title><p>
Purpose
Recent studies show that glioblastoma (GBM) is more sensitive to Temozolomide (TMZ) in the morning. In cells, inhibiting O6-Methylguanine-DNA-Methyltransferase (MGMT) abolished time-dependent TMZ efficacy, suggesting that circadian regulation of this DNA repair enzyme underlies daily TMZ sensitivity. Here, we tested the hypotheses that MGMT-promoter methylation and protein abundance vary with time-of-day in GBM, resulting in daily rhythms in TMZ efficacy.
Methods
We assessed daily rhythms in
<italic toggle="yes">Mgmt</italic>
-promoter methylation in GBM
<italic toggle="yes">in vitro</italic>
and retrospectively analyzed MGMT methylation status in human GBM biopsies collected at different times of day. Next, we measured MGMT and BMAL1 protein abundances in GBM cells collected at 4-hour intervals. To understand the therapeutic implications of circadian variations in MGMT, we incorporated its daily rhythms into an
<italic toggle="yes">in vitro</italic>
mathematical model capturing interactions between MGMT, TMZ, and GBM DNA.
Results
We found daily rhythms in
<italic toggle="yes">Mgmt</italic>
-promoter methylation and protein levels in GBM
<italic toggle="yes">in vitro</italic>
, and in patient biopsies peaking at midday. Further, MGMT protein levels peaked at CT4, corresponding to the time of maximal TMZ efficacy
<italic toggle="yes">in vitro</italic>
. When we incorporated cell-intrinsic circadian rhythms in MGMT protein into a mathematical model for GBM chemotherapy, we found that dosing when daily MGMT levels peaked and began to decline produced maximum DNA damage.
Conclusion
Our findings suggest that the likelihood of diagnosis of MGMT-promoter methylation varies with time of biopsy in GBM. Furthermore, we predict that efforts to deliver TMZ after the daily peak of MGMT activity, with exact time being dose-dependent, will significantly enhance its therapeutic efficacy.
</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>